- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06734273
Randomiseret kontrolforsøg med ærmegatrektomi med tirzepatid for at maksimere vægttab
This study examines whether adding tirzepatide-a medication that helps with weight loss-after sleeve gastrectomy surgery can help people lose more weight after the surgery; better improve conditions like Type 2 diabetes, high blood pressure, high cholesterol, and sleep apnea after surgery and; whether this causes more complications or side effects compared to surgery alone.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Tidlig fase 1
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Rush University Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adult 18 to 65 years of age
- Body Mass Index >35 with comorbidity of Type 2 Diabetes and/or Hypertension and/or Hyperlipidemia and/or Obstructive Sleep Apnea OR Body Mass Index >40 with or without comorbidity
- Undergoing primary sleeve gastrectomy
Exclusion Criteria:
- Prior metabolic and bariatric surgery
- Prior use of GLP-1 agonist
- Prior history of pancreatitis
- Personal/family history of medullary thyroid cancer or MEN type 2
- Secondary cause of obesity
- Any eating disorder
- Pregnancy/lactation
- History of acute coronary syndrome or myocardial infarction
- History of stroke
- Hepatic dysfunction: AST/ALT >3 ULN
- Renal dysfunction eGFR<45ml/min/1.73m2
- Active malignancy
- History of diabetic retinopathy
- History of gastroparesis
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: SG-T: sleeve gastrectomy with tirzepatide
In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months after surgery they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery. |
In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery. Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy. |
|
Aktiv komparator: SG-A: sleeve gastrectomy alone
In this study the control group (n=21) are patients who will undergo sleeve gastrectomy alone. |
Subjects in both the interventional group (n=21) and the control group (n=21) will undergo sleeve gastrectomy. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Vægttab
Tidsramme: 12 måneder efter operationen
|
12 måneder efter operationen
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Vægttab
Tidsramme: 18 måneder efter operationen
|
18 måneder efter operationen
|
|
|
Højt blodtryk
Tidsramme: 12 måneder efter operationen
|
12 måneder efter operationen
|
|
|
Højt blodtryk
Tidsramme: 18 måneder efter operationen
|
18 måneder efter operationen
|
|
|
Komplikationer/bivirkninger
Tidsramme: 12 måneder efter operationen
|
12 måneder efter operationen
|
|
|
Komplikationer/bivirkninger
Tidsramme: 18 måneder efter operationen
|
18 måneder efter operationen
|
|
|
Type 2 Diabetes
Tidsramme: 12 months after surgery
|
Researchers will use Hemoglobin A1c (%) to measure Type 2 Diabetes. A lower value indicates improvement. |
12 months after surgery
|
|
Type 2 Diabetes
Tidsramme: 18 months after surgery
|
Researchers will use Hemoglobin A1c (%) to measure Type 2 Diabetes. A lower value indicates improvement. |
18 months after surgery
|
|
High Cholesterol
Tidsramme: 12 months after surgery
|
Researchers will measure Cholesterol by the number of cholesterol-lowering medications needed by the subject (#). A lower value indicates improvement. |
12 months after surgery
|
|
High Cholesterol
Tidsramme: 18 months after surgery
|
Researchers will measure Cholesterol by the number of cholesterol-lowering medications needed by the subject (#). A lower value indicates improvement. |
18 months after surgery
|
|
Sleep Apnea
Tidsramme: 12 months after surgery
|
Researchers will measure Sleep Apnea by subject's need for a CPAP (continuous positive airway pressure) machine (Y/N). |
12 months after surgery
|
|
Sleep Apnea
Tidsramme: 18 months after surgery
|
Researchers will measure Sleep Apnea by subject's need for a CPAP (continuous positive airway pressure) machine (Y/N) |
18 months after surgery
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Nicholas Skertich, MD, Rush University Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Ernæringsforstyrrelser
- Overernæring
- Kropsvægt
- Overvægtig
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Tegn og symptomer
- Fedme
- Aminosyrer, peptider og proteiner
- Proteiner
- Glucagon-lignende peptid-1-receptor
- Glucagon-lignende peptidreceptorer
- Receptorer, G-protein-koblet
- Receptorer, celleoverflade
- Membranproteiner
- Receptorer, gastrointestinal hormon
- Receptorer, peptid
- Tirzepatid
Andre undersøgelses-id-numre
- 24101008
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant data (IPD) that underlie the results will be made available following publication for a period of 3 years, dependent on IRB approval to share the data and execution of a data use agreement. Access will be granted to researchers who submit a methodologically sound proposal approved by their IRB. Requests for data access can be made to the Principal Investigator.
IPD-delingstidsramme
Start: after publication. End: 3 years after publication.
IPD-delingsadgangskriterier
De-identified individual participant data (IPD) that underlie the results will be made available following publication for a period of 3 years, dependent on IRB approval to share the data and execution of a data use agreement. Access will be granted to researchers who submit a methodologically sound proposal approved by their IRB. Requests for data access can be made to the Principal Investigator.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .